Therapeutics Company;s Stock Surges After Successful FDA Meeting For Cancer Treatment
$TPST surged by 26% to close at 1.51, following Tempest's announcement of a successful end-of-phase 2 meeting with the FDA regarding Amezalpat (TPST-1120), aimed at treating first-line Hepatocellular Carcinoma.
Disclaimer: This article is intended for informational purposes only and does not constitute medical or financial advice. Readers are encouraged to conduct their own research and consult with professionals for personalized guidance.
We are working endlessly to provide free insights on the stock market every day, and greatly apprec…